BIOMAT Database Logo BIOMAT Database Logo

Phase II study of dianhydrogalactitol and ICRF-159 in patients with advanced breast cancer previously exposed to cytotoxic chemotherapy. 1977

D L Ahmann, and M J O'Connell, and H F Bisel, and J H Edmonson, and R G Hahn, and S Frytak

UI MeSH Term Description Entries
D008936 Mitolactol Alkylating antineoplastic toxic to bone marrow; used in breast cancer, also in combination with other drugs. Dibromodulcitol,NSC-104800,NSC 104800,NSC104800
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D011929 Razoxane An antimitotic agent with immunosuppressive properties. ICRF-159,ICRF-186,NSC-129943,Razoxane Mesylate, (R)-Isomer,Razoxane, (R)-Isomer,Razoxin,ICRF 159,ICRF 186,ICRF159,ICRF186,NSC 129943,NSC129943
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004376 Galactitol A naturally occurring product of plants obtained following reduction of GALACTOSE. It appears as a white crystalline powder with a slight sweet taste. It may form in excess in the lens of the eye in GALACTOSEMIAS, a deficiency of GALACTOKINASE. Dulcitol
D004988 Ethers, Cyclic Compounds of the general formula R-O-R arranged in a ring or crown formation. Cyclic Ether,Cyclic Ethers,Ether, Cyclic
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup

Related Publications

D L Ahmann, and M J O'Connell, and H F Bisel, and J H Edmonson, and R G Hahn, and S Frytak
Phase II study of ICRF-159 in patients with metastatic colorectal carcinoma previously exposed to systemic chemotherapy.
September 1976, Cancer treatment reports,
D L Ahmann, and M J O'Connell, and H F Bisel, and J H Edmonson, and R G Hahn, and S Frytak
Phase II study of ICRF-159 in refractory metastatic breast cancer.
January 1979, Cancer treatment reports,
D L Ahmann, and M J O'Connell, and H F Bisel, and J H Edmonson, and R G Hahn, and S Frytak
Phase II trial of razoxane (ICRF-159) in patients with squamous cell carcinoma of the head and neck previously exposed to systemic chemotherapy.
March 1982, Cancer treatment reports,
D L Ahmann, and M J O'Connell, and H F Bisel, and J H Edmonson, and R G Hahn, and S Frytak
Phase II study of ICRF-159 (NSC-129943) in advanced colorectal carcinoma.
January 1975, Cancer chemotherapy reports,
D L Ahmann, and M J O'Connell, and H F Bisel, and J H Edmonson, and R G Hahn, and S Frytak
Phase II study of docetaxel in patients with pancreatic cancer previously untreated with cytotoxic chemotherapy.
January 2002, Cancer investigation,
D L Ahmann, and M J O'Connell, and H F Bisel, and J H Edmonson, and R G Hahn, and S Frytak
Phase II study of ICRF-159 in non-Hodgkin's lymphomas.
March 1978, Cancer treatment reports,
D L Ahmann, and M J O'Connell, and H F Bisel, and J H Edmonson, and R G Hahn, and S Frytak
Phase II study with etoposide in previously untreated advanced breast cancer.
January 1989, Cancer chemotherapy and pharmacology,
D L Ahmann, and M J O'Connell, and H F Bisel, and J H Edmonson, and R G Hahn, and S Frytak
Phase II study of combination cytotoxic chemotherapy in advanced breast cancer: 2 years' followup.
January 1976, Cancer treatment reports,
D L Ahmann, and M J O'Connell, and H F Bisel, and J H Edmonson, and R G Hahn, and S Frytak
A study of antitumor (phase II) and immunosuppressive effects of ICRF-159 in patients with metastatic melanoma.
January 1976, Journal of clinical pharmacology,
D L Ahmann, and M J O'Connell, and H F Bisel, and J H Edmonson, and R G Hahn, and S Frytak
Combination chemotherapy for advanced colorectal cancer with triazinate, ICRF-159, 5-FU, and methyl-CCNU.
January 1980, Cancer treatment reports,
Copied contents to your clipboard!